AMYPAD publishes Centiloid guidelines and recommendations for clinical context-of-use in AD

LUXEMBOURG - Nov. 20, 2024 - PRLog -- The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective review on the interpretability and clinical application of the Centiloid (CL) scale, a robust method for measuring amyloid plaques in the brain, a key hallmark of Alzheimer's disease (AD). Published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, this work includes the context-of-use recommendations and aims to provide guidelines for the implementation of the CL scale in clinical practice, ensuring its reliability and accuracy for diagnosing and monitoring AD across different settings.

Dr. Lyduine Collij, Researcher at Amsterdam UMC and Lund University, commented that "we have summarised the available literature and AMYPAD's Centiloid Working group endeavors to propose context-of use recommendations regarding the clinical use of Centiloid to prepare the European field for the arrival of disease-modifying therapies, which will require highly accurate diagnosis to avoid unnecessary burden for patients and their families and costs for our healthcare system."

"In addition to the four Centiloid use scenarios we described, we set out to identify the remaining knowledge gaps and gathered first evidence of longitudinal investigations using the Centiloid scale, which is important as the field is moving towards early intervention." added Dr. Ariane Bollack, scientific advisor at GE HealthCare and honorary researcher at University College London.

You can read the full press release here: https://amypad.eu/news/recent-news/amypad-publishes-centi...

Acknowledgement: The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Disclaimer: This communication reflects the views of the AMYPAD Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.